Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Pharmacological approaches to target type 2 cytokines in asthma

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity); Université Toulouse III - Paul Sabatier (UT3); Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS); Pôle Clinique des Voies respiratoires CHU Toulouse; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Anticorps en thérapie et pathologie - Antibodies in Therapy and Pathology; Institut Pasteur Paris (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); Physiologie, physiopathologie et thérapeutique (ED 394); Sorbonne Université (SU); ANR-20-CE15-0026,AsthmAb,Role des IgE humaines et de leur récepteur FceRI dans l'asthme et sa potentialisation par l'obésité(2020); ANR-18-CE18-0023,AllergyVACS,Développement d'un vaccin thérapeutique pour les maladies allergiques(2018)
    • بيانات النشر:
      CCSD
      Elsevier
    • الموضوع:
      2022
    • Collection:
      Institut Pasteur: HAL
    • نبذة مختصرة :
      International audience ; Asthma is the most common chronic lung disease, affecting more than 250 million people worldwide. The heterogeneity of asthma phenotypes represents a challenge for adequate assessment and treatment of the disease. However, approximately 50% of asthma patients present with chronic type 2 inflammation initiated by alarmins, such as IL-33 and thymic stromal lymphopoietin (TSLP), and driven by the TH2 interleukins IL-4, IL-5 and IL-13. These cytokines have therefore become important therapeutic targets in asthma. Here, we discuss current knowledge on the structure and functions of these cytokines in asthma. We review preclinical and clinical data obtained with monoclonal antibodies (mAbs) targeting these cytokines or their receptors, as well as novel strategies under development, including bispecific mAbs, designed ankyrin repeat proteins (DARPins), small molecule inhibitors and vaccines targeting type 2 cytokines.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/35283171; PUBMED: 35283171
    • الرقم المعرف:
      10.1016/j.pharmthera.2022.108167
    • الدخول الالكتروني :
      https://hal.science/hal-03988416
      https://hal.science/hal-03988416v1/document
      https://hal.science/hal-03988416v1/file/S0163725822000614.pdf
      https://doi.org/10.1016/j.pharmthera.2022.108167
    • Rights:
      https://creativecommons.org/licenses/by-nc/4.0/ ; info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.24EA01F